Typhoid Fever – Pipeline Review, H2 2011

Typhoid Fever – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Typhoid Fever - Pipeline Review, H2 2011', provides an overview of the Typhoid Fever therapeutic pipeline. This report provides information on the therapeutic development for Typhoid Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Typhoid Fever. 'Typhoid Fever - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Typhoid Fever.
• A review of the Typhoid Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Typhoid Fever pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Typhoid Fever.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Typhoid Fever pipeline depth and focus of Typhoid Fever therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Typhoid Fever Overview
Therapeutics Development
An Overview of Pipeline Products for Typhoid Fever
Typhoid Fever Therapeutics under Development by Companies
Typhoid Fever Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Typhoid Fever Therapeutics – Products under Development by Companies
Typhoid Fever Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Typhoid Fever Therapeutics Development
Emergent BioSolutions Inc.
Nanotherapeutics, Inc.
Novartis AG
Celldex Therapeutics, Inc.
Bharat Biotech International Limited
Typhoid Fever – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ty800 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
GelVac - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Salmonella Typhi Vi O-acetyl Pectin-rEPA Conjugate Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
CVD 909 + Typhim Vi - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vi-rEPA(2) Conjugate Vaccine + DTP Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Typhella - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vi-CRM197 Glycoconjugated Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
FB-1811 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
FB-972 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Typhoid Vi Capsular Polysaccharide-Tetanus Toxoid Protein Conjugate Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Typhoid Fever Therapeutics – Drug Profile Updates
Typhoid Fever – Product Development Milestones
Featured News & Press Releases
Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
Apr 01, 2008: AVANT Meets Primary Endpoints For Ty800 Vaccine In Phase II Study
Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine
Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine
Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Typhoid Fever, H2 2011
Products under Development for Typhoid Fever – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Emergent BioSolutions Inc., H2 2011
Nanotherapeutics, Inc., H2 2011
Novartis AG, H2 2011
Celldex Therapeutics, Inc., H2 2011
Bharat Biotech International Limited, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Typhoid Fever Therapeutics – Drug Profile Updates

LIST OF FIGURES

Number of Products under Development for Typhoid Fever, H2 2011
Products under Development for Typhoid Fever – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top